Mariia G. Sokolova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Mariia G. Sokolova has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Ekaterina V. Lopatina
Pavlov University; Pavlov Institute of Physiology of the Russian Academy of Sciences
5 shared publications - Arthur V. Gavrichenko
Pavlov University
3 shared publications - M. A. Privalova
North-Western State Medical University n.a. I. I. Mechnikov; Hospital for War Veterans
3 shared publications - N. S. Sotnikov
North-Western State Medical University n. a. I. I. Mechnikov
3 shared publications - Natalia A. Pasatetckaia
Pavlov University; Institute of experimental medicine
3 shared publications - Yu. I. Polyakov
Pavlov Institute of Physiology RAS, First Pavlov State Medical University of St. Petersburg, North-Western State Medical University named after I.I. Mechnikov
3 shared publications
Latest Publications
- Open Access
- 27 March 2026
- Published by ECO-Vector LLC (Publications) in Medical academic journal
- Vol. 26 (1) , 5-13
The physiological role of the dystrophin protein and pathological conditions in its deficiency
Dystrophin is a crucial structural rod-shaped protein that stabilizes muscle cell membranes and ensures the normal functioning of skeletal musculature. It is an integral component of the dystrophin-associated glycoprotein complex, which serves as a molecular link connecting the myocyte cytoskeleton to the extracellular matrix. Mutations in the DMD gene, located on the short arm of the X chromosome (Xp21.2), result in the complete or partial loss of dystrophin expression. This deficiency compromises sarcolemmal integrity, leading to uncontrolled calcium influx into the cell, subsequent myocyte destruction, oxidative stress, and chronic inflammation. These pathological cascades are accompanied by progressive necrosis of muscle fibers and their gradual replacement by connective and adipose tissue. The most severe clinical manifestation of dystrophin deficiency is Duchenne muscular dystrophy, an X-linked hereditary neuromuscular disorder with an incidence of approximately one in 3500 to 5000 live male births. The disease is characterized by relentless progression, culminating in the loss of ambulation, respiratory insufficiency, and the development of cardiomyopathy. Current scientific perspectives on dystrophin function extend significantly beyond the mechanical stabilization of muscle tissue. Recent studies indicate that this protein plays a critical role in systemic lipid metabolism and central nervous system activity, thereby elucidating the presence of cognitive disorders and metabolic disturbances in patients. This review provides comprehensive information on the structural organization of dystrophin isoforms, the molecular architecture of the dystrophin-associated protein complex, and a detailed analysis of the pathophysiological processes associated with dystrophin deficiency.
- 27 March 2026
- Published by ECO-Vector LLC (Publications) in Medical academic journal
- Vol. 26 (1) , 5-13
Open AccessThe physiological role of the dystrophin protein and pathological conditions in its deficiency
Dystrophin is a crucial structural rod-shaped protein that stabilizes muscle cell membranes and ensures the normal functioning of skeletal musculature. It is an integral component of the dystrophin-associated glycoprotein complex, which serves as a molecular link connecting the myocyte cytoskeleton to the extracellular matrix. Mutations in the DMD gene, located on the short arm of the X chromosome (Xp21.2), result in the complete or partial loss of dystrophin expression. This deficiency compromises sarcolemmal integrity, leading to uncontrolled calcium influx into the cell, subsequent myocyte destruction, oxidative stress, and chronic inflammation. These pathological cascades are accompanied by progressive necrosis of muscle fibers and their gradual replacement by connective and adipose tissue. The most severe clinical manifestation of dystrophin deficiency is Duchenne muscular dystrophy, an X-linked hereditary neuromuscular disorder with an incidence of approximately one in 3500 to 5000 live male births. The disease is characterized by relentless progression, culminating in the loss of ambulation, respiratory insufficiency, and the development of cardiomyopathy. Current scientific perspectives on dystrophin function extend significantly beyond the mechanical stabilization of muscle tissue. Recent studies indicate that this protein plays a critical role in systemic lipid metabolism and central nervous system activity, thereby elucidating the presence of cognitive disorders and metabolic disturbances in patients. This review provides comprehensive information on the structural organization of dystrophin isoforms, the molecular architecture of the dystrophin-associated protein complex, and a detailed analysis of the pathophysiological processes associated with dystrophin deficiency.
- Open Access
- 16 September 2025
- Published by FSBEI HE I.P. Pavlov SPbSMU MOH Russia in The Scientific Notes of the Pavlov University
- Vol. 32 (2) , 100-112
X-linked adrenoleukodystrophy: literature review, description of clinical cases
X-linked adrenoleukodystrophy (X-ALD) is an orphan hereditary disease belonging to the group of peroxisomal diseases with an X-linked recessive type of inheritance, associated with mutations in the ABCD1 gene, characterized by combined damage to the nervous system and adrenal glands. The article provides a review of the literature on this nosology with a description of the etiopathogenesis, clinical picture, diagnostic methods, differential diagnosis and treatment options for this disease. The article describes clinical cases of three patients who were hospitalized in the neurological department № 2 of Pavlov University between 2018 and 2024, based on their complaints, neurological examination data, and laboratory and instrumental diagnostic methods, they were diagnosed with X-ALD. In all the presented clinical cases, more than 3 years passed from the onset of the first symptoms to the final diagnosis, which is due to the difficulty of diagnosing X-ALD at early stages due to the polymorphism of the clinical picture: from classical manifestations of encephalopathy to infrequently encountered manifestations of myelopathy and polyneuropathic syndrome in this nosology. In this regard, timely diagnosis of the disease is important, since effective disease-modifying treatment methods can only be effective if therapy is started in a timely manner.
- 16 September 2025
- Published by FSBEI HE I.P. Pavlov SPbSMU MOH Russia in The Scientific Notes of the Pavlov University
- Vol. 32 (2) , 100-112
Open AccessX-linked adrenoleukodystrophy: literature review, description of clinical cases
X-linked adrenoleukodystrophy (X-ALD) is an orphan hereditary disease belonging to the group of peroxisomal diseases with an X-linked recessive type of inheritance, associated with mutations in the ABCD1 gene, characterized by combined damage to the nervous system and adrenal glands. The article provides a review of the literature on this nosology with a description of the etiopathogenesis, clinical picture, diagnostic methods, differential diagnosis and treatment options for this disease. The article describes clinical cases of three patients who were hospitalized in the neurological department № 2 of Pavlov University between 2018 and 2024, based on their complaints, neurological examination data, and laboratory and instrumental diagnostic methods, they were diagnosed with X-ALD. In all the presented clinical cases, more than 3 years passed from the onset of the first symptoms to the final diagnosis, which is due to the difficulty of diagnosing X-ALD at early stages due to the polymorphism of the clinical picture: from classical manifestations of encephalopathy to infrequently encountered manifestations of myelopathy and polyneuropathic syndrome in this nosology. In this regard, timely diagnosis of the disease is important, since effective disease-modifying treatment methods can only be effective if therapy is started in a timely manner.
- 8 November 2023
- Published by Alfmed LLC in Medical alphabet
- No. 26,p. 35-40
Analysis of the effect of intensive therapy of premature infants on the development of neonatal retinopathy
Retinopathy of prematurity is one of the most severe diseases that lead to permanent blindness from early childhood. The frequency of retinopathy of prematurity in neonatology closely correlates with the degree of maturity of the child’s body.Goal. To conduct a analysis of the correlation of the degree of oxygenation, the number of blood transfusions with the severity of progressive retinopathy in newborns. The study included 40 premature infants diagnosed with retinopathy of newborns who were being treated in the neonatal intensive care unit. Conducted: clinical and diagnostic examination of patients; analysis of the dependence of the degree of oxygenation, the number of blood transfusions, gestational age, inotropic support and the severity of retinopathy.Materials and methods. Out of 40 patients diagnosed with neonatal retinopathy, 6 children were operated on.Results and discussion. The study showed that all the operated children were born at a gestation period of less than 29 weeks, were treated with antibacterial and inotropic drugs. There was no direct relationship between the number of blood transfusions and the risk of developing a severe form of the disease with further surgical treatment. In 40% of cases, children who developed retinopathy of stages 1 and 2 did not receive transfusion of erythrocyte suspension at all. At the treatment stage, all operated patients received a gas-air mixture with an oxygen content above 45%, as well as inotropic and vasopressor support with epinephrine and norepinephrine. Statistical analysis has shown that the number of blood transfusions is not the leading factor in the decision to refer a child for surgery. Among children with a gestation period of less than 29 weeks, retinopathy of varying severity was found in all infants; in the group of children aged 30–35 weeks, the disease developed only in 45% of patients.Conclusion. The conducted studies have shown that the parameter number of hours spent using IVL (the parameter artificial lung ventilation) is informative, and parameters such as weight and gestational age are significant.It is necessary to note the importance of additional parameters. Among the operated children, the condition of severe asphyxia was suffered by 45.5% of children in group A, in Weight groups severe asphyxia was in 28% of cases. Statistical analysis showed that children who required surgical treatment received catecholamine therapy at the initial stages. The most unfavorable percentage of oxygen supplied with the air mixture starts from 40–45%. The children who required surgical treatment received catecholamine therapy at the initial stages.
- 8 November 2023
- Published by Alfmed LLC in Medical alphabet
- No. 26,p. 35-40
Analysis of the effect of intensive therapy of premature infants on the development of neonatal retinopathy
Retinopathy of prematurity is one of the most severe diseases that lead to permanent blindness from early childhood. The frequency of retinopathy of prematurity in neonatology closely correlates with the degree of maturity of the child’s body.Goal. To conduct a analysis of the correlation of the degree of oxygenation, the number of blood transfusions with the severity of progressive retinopathy in newborns. The study included 40 premature infants diagnosed with retinopathy of newborns who were being treated in the neonatal intensive care unit. Conducted: clinical and diagnostic examination of patients; analysis of the dependence of the degree of oxygenation, the number of blood transfusions, gestational age, inotropic support and the severity of retinopathy.Materials and methods. Out of 40 patients diagnosed with neonatal retinopathy, 6 children were operated on.Results and discussion. The study showed that all the operated children were born at a gestation period of less than 29 weeks, were treated with antibacterial and inotropic drugs. There was no direct relationship between the number of blood transfusions and the risk of developing a severe form of the disease with further surgical treatment. In 40% of cases, children who developed retinopathy of stages 1 and 2 did not receive transfusion of erythrocyte suspension at all. At the treatment stage, all operated patients received a gas-air mixture with an oxygen content above 45%, as well as inotropic and vasopressor support with epinephrine and norepinephrine. Statistical analysis has shown that the number of blood transfusions is not the leading factor in the decision to refer a child for surgery. Among children with a gestation period of less than 29 weeks, retinopathy of varying severity was found in all infants; in the group of children aged 30–35 weeks, the disease developed only in 45% of patients.Conclusion. The conducted studies have shown that the parameter number of hours spent using IVL (the parameter artificial lung ventilation) is informative, and parameters such as weight and gestational age are significant.It is necessary to note the importance of additional parameters. Among the operated children, the condition of severe asphyxia was suffered by 45.5% of children in group A, in Weight groups severe asphyxia was in 28% of cases. Statistical analysis showed that children who required surgical treatment received catecholamine therapy at the initial stages. The most unfavorable percentage of oxygen supplied with the air mixture starts from 40–45%. The children who required surgical treatment received catecholamine therapy at the initial stages.
- 6 November 2023
- Published by Alfmed LLC in Medical alphabet
- No. 21,p. 54-60
Clinical observation of patient with moya-moya syndrome complicated by transient ischemic attack followed by development of hemorrhagic stroke. Features of diagnosis and treatment
Moya-moya syndrome is a chronic cerebrovascular disease associated with narrowing of the arteries of the brain, manifested by headache, epileptic seizures, transient ischemic attack, leading to the development of ischemic or hemorrhagic stroke. To date, the main pathogenetic mechanisms of moya-moya syndrome have not yet been fully identified, but some studies have shown that an important component of the development of moya-moya is a genetic factor. However, if the issue of diagnosis of this syndrome can be considered solved – it is the use of neuroimaging methods (MRI, CT) with contrast of cerebral vessels, then the issue of treatment remains relevant. The article presents a clinical case of a patient with moya-moya syndrome with the transformation of an ischemic stroke into a hemorrhagic type.
- 6 November 2023
- Published by Alfmed LLC in Medical alphabet
- No. 21,p. 54-60
Clinical observation of patient with moya-moya syndrome complicated by transient ischemic attack followed by development of hemorrhagic stroke. Features of diagnosis and treatment
Moya-moya syndrome is a chronic cerebrovascular disease associated with narrowing of the arteries of the brain, manifested by headache, epileptic seizures, transient ischemic attack, leading to the development of ischemic or hemorrhagic stroke. To date, the main pathogenetic mechanisms of moya-moya syndrome have not yet been fully identified, but some studies have shown that an important component of the development of moya-moya is a genetic factor. However, if the issue of diagnosis of this syndrome can be considered solved – it is the use of neuroimaging methods (MRI, CT) with contrast of cerebral vessels, then the issue of treatment remains relevant. The article presents a clinical case of a patient with moya-moya syndrome with the transformation of an ischemic stroke into a hemorrhagic type.
- 31 October 2022
- Published by Alfmed LLC in Medical alphabet
- No. 21,p. 18-22
Clinical and physiological aspects of bruxism and its rational pharmacotherapy
Objective. Clinical-neurophysiological and neuropsychological examination of patients with bruxism was conducted to determine the functional condition of the peripheral and central trigeminal nerve and to justify the combined therapy.Materials and methods. 26 patients (14 women and 12 men) aged 20 to 50 years with complaints and typical neurological symptoms of bruxism were examined. The control group consisted of 30 volunteers in the age from 24 to 35 years, who underwent a comprehensive examination as part of a medical check-up, who did not have severe somatic, neurological or mental diseases and did not have complaints of impaired function of the masticatory muscles. Clinical and neurological, electrophysiological and neuropsychological diagnostic methods were used in the trial. Quantitative sensory testing was performed using TSA II device (Medoc, Israel), and temperature sensitivity thresholds were determined using the Marstok method on symmetrical facial areas according to the Zelder zones. Diagnostics of the functional condition of the masticatory muscles was carried out using a computer neuroelectromyograph M-Test ‘DX-Systems’ and a computer system for analyzingelectromyographic records. Electroencephalography (EEG) was performed using 16-channel computer electroencephalography system. C. D. Spielberger scale adapted by Yu. L. Khanin (C. D. Spielberger, 2010) was used to determine the level of anxiety. The results were processed using Statistica and Microsoft Excel 2015 programs.Results. Patients with bruxism had a high level of personal anxiety, which was found in 73 % of the participants. Determination of the thresholds of cold sensitivity on the faces of patients with bruxism showed a lower threshold of cold sensitivity in the lateral parts and a higher threshold in the oral parts. Electromyography of masticatory muscles showed an increase in the duration of mastication period, a decrease in the masticatory rhythm, a decrease in masticatory efficiency, and irrational functioning of the masticatory muscles of varying severity in the patients of the examined group. Assessment of brain biopotentials showed an increase in the ascending activating effects of nonspecific median brain structures (72 %). The data obtained helped to obtain a comprehensive assessment of functional condition of the trigeminal nerve in patients with bruxism and to justify pharmaceutical therapy aimed at both the muscular apparatus (muscle relaxants) and the peripheral and central parts of the trigeminal nerve (antiepileptic drugs) in combination with a medicine that has a stabilizing effect on the functional condition of neurons and normalization of bioelectric processes in the central nervous system (correctors of metabolism).
- 31 October 2022
- Published by Alfmed LLC in Medical alphabet
- No. 21,p. 18-22
Clinical and physiological aspects of bruxism and its rational pharmacotherapy
Objective. Clinical-neurophysiological and neuropsychological examination of patients with bruxism was conducted to determine the functional condition of the peripheral and central trigeminal nerve and to justify the combined therapy.Materials and methods. 26 patients (14 women and 12 men) aged 20 to 50 years with complaints and typical neurological symptoms of bruxism were examined. The control group consisted of 30 volunteers in the age from 24 to 35 years, who underwent a comprehensive examination as part of a medical check-up, who did not have severe somatic, neurological or mental diseases and did not have complaints of impaired function of the masticatory muscles. Clinical and neurological, electrophysiological and neuropsychological diagnostic methods were used in the trial. Quantitative sensory testing was performed using TSA II device (Medoc, Israel), and temperature sensitivity thresholds were determined using the Marstok method on symmetrical facial areas according to the Zelder zones. Diagnostics of the functional condition of the masticatory muscles was carried out using a computer neuroelectromyograph M-Test ‘DX-Systems’ and a computer system for analyzingelectromyographic records. Electroencephalography (EEG) was performed using 16-channel computer electroencephalography system. C. D. Spielberger scale adapted by Yu. L. Khanin (C. D. Spielberger, 2010) was used to determine the level of anxiety. The results were processed using Statistica and Microsoft Excel 2015 programs.Results. Patients with bruxism had a high level of personal anxiety, which was found in 73 % of the participants. Determination of the thresholds of cold sensitivity on the faces of patients with bruxism showed a lower threshold of cold sensitivity in the lateral parts and a higher threshold in the oral parts. Electromyography of masticatory muscles showed an increase in the duration of mastication period, a decrease in the masticatory rhythm, a decrease in masticatory efficiency, and irrational functioning of the masticatory muscles of varying severity in the patients of the examined group. Assessment of brain biopotentials showed an increase in the ascending activating effects of nonspecific median brain structures (72 %). The data obtained helped to obtain a comprehensive assessment of functional condition of the trigeminal nerve in patients with bruxism and to justify pharmaceutical therapy aimed at both the muscular apparatus (muscle relaxants) and the peripheral and central parts of the trigeminal nerve (antiepileptic drugs) in combination with a medicine that has a stabilizing effect on the functional condition of neurons and normalization of bioelectric processes in the central nervous system (correctors of metabolism).
- Open Access
- 10 October 2022
- Published by ECO-Vector LLC in Annals of Clinical and Experimental Neurology
- Vol. 16 (3) , 41-46
The myoprotective effect of non-quantal acetylcholine: in vitro model of the myopathy component of chronic inflammatory demyelinating polyneuropathy
Introduction. Chronic inflammatory demyelinating polyneuropathy (CIDP) is one of the most common primary polyneuropathies. A degenerative process is the underlying cause of muscular atrophy in CIDP, while muscle strength may not fully recover in patients after pathogenesis-based treatment, thus extending the period of disability. Information about factors affecting the trophic function of muscles can be used to treat neuromuscular disorders. Study aim to examine the trophotropic properties of the study participants' blood plasma and the myoprotective effect of acetylcholine concentration equivalent to non-quantal release, using an in vitro model of the myopathy component of CIDP. Materials and methods. The study included 25 patients diagnosed with typical CIDP in accordance with the EFNS/PNS 2010 criteria. The control group consisted of 25 healthy individuals. Serum antibody levels to the nicotinic acetylcholine receptor were measured in all study participants. A method for organotypic cultivation of skeletal muscle tissue and an in vitro model of the myopathy component of CIPD were developed. The effect of the study participants' blood plasma on the growth of skeletal muscle explants in organotypic culture was assessed. Results. Patients with CIPD were found to have symmetrical sensorimotor polyneuropathy of varying severity (100%); muscle atrophy (88%), and sensory ataxia (84%). The median INCAT Overall Disability Sum Score was 2 [1; 3] for the arms and 3 [2; 5] for the legs. The median Neurological Impairment Scale (NIS) score was 17 [10; 34]. The nicotinic acetylcholine receptor antibody levels were higher in patients with CIDP (0.47 [0.31; 0.54] nmol/l) than in the control group (0.02 [0.01; 0.03] nmol/l). For the first time, a myotoxic effect of the blood plasma from patients with CIDP was observed in organotypic skeletal muscle culture. Using 1:70 and 1:100 dilutions, patient blood plasma inhibited the growth of explants by 27% (n = 120; p 0.001) and 21% (n = 120; p 0.001), respectively. This myotoxic effect removed acetylcholine at a concentration equivalent to non-quantal release (108 М). Conclusion. These results expand our understanding of skeletal muscle damage in CIPD and the role of non-quantal acetylcholine in regulating skeletal muscle growth.
- 10 October 2022
- Published by ECO-Vector LLC in Annals of Clinical and Experimental Neurology
- Vol. 16 (3) , 41-46
Open AccessThe myoprotective effect of non-quantal acetylcholine: in vitro model of the myopathy component of chronic inflammatory demyelinating polyneuropathy
Introduction. Chronic inflammatory demyelinating polyneuropathy (CIDP) is one of the most common primary polyneuropathies. A degenerative process is the underlying cause of muscular atrophy in CIDP, while muscle strength may not fully recover in patients after pathogenesis-based treatment, thus extending the period of disability. Information about factors affecting the trophic function of muscles can be used to treat neuromuscular disorders. Study aim to examine the trophotropic properties of the study participants' blood plasma and the myoprotective effect of acetylcholine concentration equivalent to non-quantal release, using an in vitro model of the myopathy component of CIDP. Materials and methods. The study included 25 patients diagnosed with typical CIDP in accordance with the EFNS/PNS 2010 criteria. The control group consisted of 25 healthy individuals. Serum antibody levels to the nicotinic acetylcholine receptor were measured in all study participants. A method for organotypic cultivation of skeletal muscle tissue and an in vitro model of the myopathy component of CIPD were developed. The effect of the study participants' blood plasma on the growth of skeletal muscle explants in organotypic culture was assessed. Results. Patients with CIPD were found to have symmetrical sensorimotor polyneuropathy of varying severity (100%); muscle atrophy (88%), and sensory ataxia (84%). The median INCAT Overall Disability Sum Score was 2 [1; 3] for the arms and 3 [2; 5] for the legs. The median Neurological Impairment Scale (NIS) score was 17 [10; 34]. The nicotinic acetylcholine receptor antibody levels were higher in patients with CIDP (0.47 [0.31; 0.54] nmol/l) than in the control group (0.02 [0.01; 0.03] nmol/l). For the first time, a myotoxic effect of the blood plasma from patients with CIDP was observed in organotypic skeletal muscle culture. Using 1:70 and 1:100 dilutions, patient blood plasma inhibited the growth of explants by 27% (n = 120; p 0.001) and 21% (n = 120; p 0.001), respectively. This myotoxic effect removed acetylcholine at a concentration equivalent to non-quantal release (108 М). Conclusion. These results expand our understanding of skeletal muscle damage in CIPD and the role of non-quantal acetylcholine in regulating skeletal muscle growth.
- 8 June 2022
- Published by Alfmed LLC in Medical alphabet
- No. 10,p. 12-16
Clinical and laboratory rationale for use of correctors of metabolism for treatment of patients with new coronavirus infection COVID-19 in acute period with background of cerebrovascular disease
Objective. The aim of the study was to evaluate the effectiveness of the drug Mildronate in the complex therapy of patients with a new coronavirus infection COVID-19 in the acute period and the background of cerebrovascular disease.Material and methods. The material for the study was the medical records of 210 patients (140 women and 70 men) who had COVID-19 coronavirus infection against the background of cerebrovascular pathology in the period from 04.10.2020 to 12.31.2021. 120 patients (75 women and 45 men) received the drug Mildronate as part of complex therapy, 90 patients (55 women 35 men) made up the control group, received complex treatment without the use of the drug Mildronate. Patients in both groups were comparable in age, the average age was 76.5 years (from 50 to 93 years). Groups according to nosological forms were distributed as follows: in the main group – ischemic stroke of various localization – 70 patients (48 women and 22 men), chronic cerebrovascular insufficiency of varying severity – 50 patients (27 women and 23 men); in the control group – ischemic stroke of various localization was in 50 patients (36 women and 14 men), chronic cerebrovascular insufficiency – 40 patients (19 women and 21 men). To correct chronic hypoxia, the drug Mildronate was chosen, which is a blocker of fatty acid oxidation, has a multicomponent effect, stabilizes microcirculation under conditions of ischemia and hypoxia. Also, Mildronate is one of the universal cytoprotectors with a pronounced neuro-, cardio- and angioprotective effect, which goes well with drugs of other pharmacological groups.Results. The drug Mildronate is a blocker of fatty acid oxidation, has a multicomponent effect, stabilizes microcirculation in conditions of ischemia and hypoxia. According to the observations, it can be noted that the neurological status during mildronate therapy has a more significant regression trend with good rehabilitation potential – 56.0% of patients can serve themselves independently, while patients in the control group reached a level of 9 points only in 51.0% of cases. A significant neurological defect remained in the main group in 6.2% of patients, in the control group this figure was 8.8%.
- 8 June 2022
- Published by Alfmed LLC in Medical alphabet
- No. 10,p. 12-16
Clinical and laboratory rationale for use of correctors of metabolism for treatment of patients with new coronavirus infection COVID-19 in acute period with background of cerebrovascular disease
Objective. The aim of the study was to evaluate the effectiveness of the drug Mildronate in the complex therapy of patients with a new coronavirus infection COVID-19 in the acute period and the background of cerebrovascular disease.Material and methods. The material for the study was the medical records of 210 patients (140 women and 70 men) who had COVID-19 coronavirus infection against the background of cerebrovascular pathology in the period from 04.10.2020 to 12.31.2021. 120 patients (75 women and 45 men) received the drug Mildronate as part of complex therapy, 90 patients (55 women 35 men) made up the control group, received complex treatment without the use of the drug Mildronate. Patients in both groups were comparable in age, the average age was 76.5 years (from 50 to 93 years). Groups according to nosological forms were distributed as follows: in the main group – ischemic stroke of various localization – 70 patients (48 women and 22 men), chronic cerebrovascular insufficiency of varying severity – 50 patients (27 women and 23 men); in the control group – ischemic stroke of various localization was in 50 patients (36 women and 14 men), chronic cerebrovascular insufficiency – 40 patients (19 women and 21 men). To correct chronic hypoxia, the drug Mildronate was chosen, which is a blocker of fatty acid oxidation, has a multicomponent effect, stabilizes microcirculation under conditions of ischemia and hypoxia. Also, Mildronate is one of the universal cytoprotectors with a pronounced neuro-, cardio- and angioprotective effect, which goes well with drugs of other pharmacological groups.Results. The drug Mildronate is a blocker of fatty acid oxidation, has a multicomponent effect, stabilizes microcirculation in conditions of ischemia and hypoxia. According to the observations, it can be noted that the neurological status during mildronate therapy has a more significant regression trend with good rehabilitation potential – 56.0% of patients can serve themselves independently, while patients in the control group reached a level of 9 points only in 51.0% of cases. A significant neurological defect remained in the main group in 6.2% of patients, in the control group this figure was 8.8%.
- 26 December 2021
- Published by Alfmed LLC in Medical alphabet
- No. 36,p. 47-51
Retrospective analysis of cerebral neurological complications against background of seasonal respiratory viral infections and new coronavirus infection Covid‑19
Based on the example of seasonal epidemics of respiratory viral infections, it is partially possible to model the outcomes of neurological complications from Covid‑19, taking into account the pathogenetic features of the virus effect on the vascular wall and nerve cells. The accumulated experience of doctors of various specialties makes it possible to prevent such life-threatening complications as ACVA, PATE, intoxication, and sepsis. From the first days of the disease, it is necessary to conduct dynamic monitoring of blood rheology, the level of systemic oxygenation, use anticoagulants in preventive doses in patients at the early stages of the disease, conduct therapy aimed at reducing the risk of cytokine storm development.
- 26 December 2021
- Published by Alfmed LLC in Medical alphabet
- No. 36,p. 47-51
Retrospective analysis of cerebral neurological complications against background of seasonal respiratory viral infections and new coronavirus infection Covid‑19
Based on the example of seasonal epidemics of respiratory viral infections, it is partially possible to model the outcomes of neurological complications from Covid‑19, taking into account the pathogenetic features of the virus effect on the vascular wall and nerve cells. The accumulated experience of doctors of various specialties makes it possible to prevent such life-threatening complications as ACVA, PATE, intoxication, and sepsis. From the first days of the disease, it is necessary to conduct dynamic monitoring of blood rheology, the level of systemic oxygenation, use anticoagulants in preventive doses in patients at the early stages of the disease, conduct therapy aimed at reducing the risk of cytokine storm development.
- 26 December 2021
- Published by Alfmed LLC in Medical alphabet
- No. 36,p. 7-11
Clinical and neurophysiological correlations in post-Covid‑19 patients and rationale for pathogenetic therapy
Clinical and neurological, neurophysiological, and neuropsychological examination of 50 patients aged 50–65 y. o. with an experience of COVID‑19 infection within the last 3 to 6 months, revealed pathological changes in the central nervous system in the form of cerebrastenic and autonomic disorders, motor disorders, vestibulopathy symptoms, which occurred in various combinations, with astheno-vegetative syndrome as obligate. Cognitive impairments were detected in 26% of patients; the mental fatigability index was 1.055 ± 0.124; a high level of situational anxiety was noted in 35% of patients, and a high level of personal anxiety in 50 % of patients with the experience of COVID‑19. The study of brain biopotentials revealed moderate diffuse changes (18%) and irritative disorders on the part of hypothalamic (69 %) and diencephalic structures (20%). All of the above may indicate that, regardless of the form of coronavirus infection occurred in humans, i. e., latent, mild, moderate or severe, one of the targets of the pathological impact of COVID‑19 virus is the median structures of the brain responsible for autonomic and cognitive functions. Nevertheless, in our opinion, these disorders are associated not with a direct pathological effect, but are mediated mainly by circulatory disorders in the microcirculatory bed due to endothelial damage and are rather functional disorders on the part of the central nervous system. This provides the grounds for the selection of pathogenetic therapy aimed at stabilizing the functional state of neurons, and one of the drugs of choice may be citicoline (Noocyl), the action of which is associated with reinforcing the cell membrane of the neuron and normalizing bioelectric processes.
- 26 December 2021
- Published by Alfmed LLC in Medical alphabet
- No. 36,p. 7-11
Clinical and neurophysiological correlations in post-Covid‑19 patients and rationale for pathogenetic therapy
Clinical and neurological, neurophysiological, and neuropsychological examination of 50 patients aged 50–65 y. o. with an experience of COVID‑19 infection within the last 3 to 6 months, revealed pathological changes in the central nervous system in the form of cerebrastenic and autonomic disorders, motor disorders, vestibulopathy symptoms, which occurred in various combinations, with astheno-vegetative syndrome as obligate. Cognitive impairments were detected in 26% of patients; the mental fatigability index was 1.055 ± 0.124; a high level of situational anxiety was noted in 35% of patients, and a high level of personal anxiety in 50 % of patients with the experience of COVID‑19. The study of brain biopotentials revealed moderate diffuse changes (18%) and irritative disorders on the part of hypothalamic (69 %) and diencephalic structures (20%). All of the above may indicate that, regardless of the form of coronavirus infection occurred in humans, i. e., latent, mild, moderate or severe, one of the targets of the pathological impact of COVID‑19 virus is the median structures of the brain responsible for autonomic and cognitive functions. Nevertheless, in our opinion, these disorders are associated not with a direct pathological effect, but are mediated mainly by circulatory disorders in the microcirculatory bed due to endothelial damage and are rather functional disorders on the part of the central nervous system. This provides the grounds for the selection of pathogenetic therapy aimed at stabilizing the functional state of neurons, and one of the drugs of choice may be citicoline (Noocyl), the action of which is associated with reinforcing the cell membrane of the neuron and normalizing bioelectric processes.
- 29 September 2021
- Published by Alfmed LLC in Medical alphabet
- No. 22,p. 51-54-54
Experience of joint management of patient with Huntington's chorea by neurological and dental specialists with use of tetrabenazine
Huntington's chorea is a hereditary disease causing progressive degeneration of the central nervous system with the damage to extrapyramidal structures: basal nuclei, striatum, subthalamic nucleus with increased activity of the central dopaminergic pathways, with the development of neurological, psychiatric, and emotional/personality disorders [1, 17]. The inheritance pattern of the disorder is autosomal dominance. The prevalence of Huntington's disease ranges from 3 to 17 cases per 100,000 population, averaging 5–7 cases per 100,000 population in Russia [2]. The development of the disease is associated with the expansion of CAG (cytosine-adenine-guanine) trinucleotide repeats in the frst exon of the HTT gene encoding the huntingtin protein. This expansion of trinucleotides (long sections of glutamine residues) leads to the selective loss of neurons that connect the striatum and the globus pallidus. This leads to a loss of inhibitory activity and an increase in the excitation impulse, which leads to uncontrolled movements.Unfortunately, medical treatment does not slow down the progression of this disease (a lethal outcome occurs within 15–20 years). Improvement of the quality of life of people with Huntington's chorea, with the provision of medical services at an appropriate level, remains an urgent issue. This direction is especially relevant in providing dental care to patients with Huntington's chorea. Due to the pronounced hyperkinetic syndrome and compulsive movements in the muscles of the arms, trunk, neck and face, it is almost impossible to provide dental care for these patients. Currently, general anesthesia is used to enable dental intervention, but patients note that with frequent use of anesthesia, the patient's condition deteriorates, with an increase in hyperkinetic symptoms. Tetrabenazine is known to reduce the severity of hyperkinetic symptoms and is used in many countries [5].However, in our country many specialists are not familiar with it. During the follow-up of a patient with Huntington's chorea, with the selection of a therapeutic dose of tetrabenazine, it was possible to provide three stages of dental care for the patient without the use of general anesthesia. The material presented in the article can provide useful information on the use of tetrabenazine in patients with Huntington's chorea.
- 29 September 2021
- Published by Alfmed LLC in Medical alphabet
- No. 22,p. 51-54-54
Experience of joint management of patient with Huntington's chorea by neurological and dental specialists with use of tetrabenazine
Huntington's chorea is a hereditary disease causing progressive degeneration of the central nervous system with the damage to extrapyramidal structures: basal nuclei, striatum, subthalamic nucleus with increased activity of the central dopaminergic pathways, with the development of neurological, psychiatric, and emotional/personality disorders [1, 17]. The inheritance pattern of the disorder is autosomal dominance. The prevalence of Huntington's disease ranges from 3 to 17 cases per 100,000 population, averaging 5–7 cases per 100,000 population in Russia [2]. The development of the disease is associated with the expansion of CAG (cytosine-adenine-guanine) trinucleotide repeats in the frst exon of the HTT gene encoding the huntingtin protein. This expansion of trinucleotides (long sections of glutamine residues) leads to the selective loss of neurons that connect the striatum and the globus pallidus. This leads to a loss of inhibitory activity and an increase in the excitation impulse, which leads to uncontrolled movements.Unfortunately, medical treatment does not slow down the progression of this disease (a lethal outcome occurs within 15–20 years). Improvement of the quality of life of people with Huntington's chorea, with the provision of medical services at an appropriate level, remains an urgent issue. This direction is especially relevant in providing dental care to patients with Huntington's chorea. Due to the pronounced hyperkinetic syndrome and compulsive movements in the muscles of the arms, trunk, neck and face, it is almost impossible to provide dental care for these patients. Currently, general anesthesia is used to enable dental intervention, but patients note that with frequent use of anesthesia, the patient's condition deteriorates, with an increase in hyperkinetic symptoms. Tetrabenazine is known to reduce the severity of hyperkinetic symptoms and is used in many countries [5].However, in our country many specialists are not familiar with it. During the follow-up of a patient with Huntington's chorea, with the selection of a therapeutic dose of tetrabenazine, it was possible to provide three stages of dental care for the patient without the use of general anesthesia. The material presented in the article can provide useful information on the use of tetrabenazine in patients with Huntington's chorea.